Celyad Oncology SA (CYAD)

NASDAQ: CYAD · IEX Real-Time Price · USD
1.04
+0.01 (1.34%)
At close: Dec 9, 2022 4:00 PM
1.00
-0.04 (-3.85%)
After-hours: Dec 9, 2022 4:18 PM EST
1.34%
Market Cap 26.01M
Revenue (ttm) n/a
Net Income (ttm) -27.07M
Shares Out 22.59M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,679
Open 0.98
Previous Close 1.03
Day's Range 0.98 - 1.04
52-Week Range 0.95 - 4.96
Beta 0.94
Analysts Sell
Price Target 2.86 (+175.0%)
Earnings Date n/a

About CYAD

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate t... [Read more]

Industry Biotechnology
Founded 2004
CEO Filippo Petti
Employees 95
Stock Exchange NASDAQ
Ticker Symbol CYAD
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CYAD stock is "Sell." The 12-month stock price forecast is 2.86, which is an increase of 175.00% from the latest price.

Price Target
$2.86
(175.00% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of chimeric ...

4 weeks ago - GlobeNewsWire

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic will acquire Celyad Oncology's GMP grade cell therapy manufacturing capability, including the existing facility and all relat...

2 months ago - Business Wire

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developme...

4 months ago - GlobeNewsWire

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

4 months ago - GlobeNewsWire

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

4 months ago - GlobeNewsWire

Celyad Oncology Announces Leadership Updates

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developme...

5 months ago - GlobeNewsWire

Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

6 months ago - Zacks Investment Research

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developmen...

6 months ago - GlobeNewsWire

CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Qua...

7 months ago - GlobeNewsWire

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developmen...

7 months ago - GlobeNewsWire

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on ...

8 months ago - Business Wire

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, March 02, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developm...

9 months ago - GlobeNewsWire

Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developme...

9 months ago - GlobeNewsWire

Celyad Oncology Announces February 2022 Conference Schedule

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

10 months ago - Business Wire

Celyad Oncology Provides Outlook for 2022

MONT-SAINT-GUIBERT, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

10 months ago - GlobeNewsWire

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Other symbols: APTOCELUCNSPSPRB
11 months ago - Zacks Investment Research

Celyad Oncology Announces January 2022 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

11 months ago - GlobeNewsWire

Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

11 months ago - GlobeNewsWire

Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and developme...

11 months ago - GlobeNewsWire

Transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

11 months ago - GlobeNewsWire

Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

11 months ago - Business Wire

Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate

MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the discovery a...

1 year ago - GlobeNewsWire

Hot Biotech Stocks: Why Celyad Oncology (CYAD) Is Soaring Higher Today

Celyad Oncology (CYAD) stock is heading higher on Friday following the announcement of a $32.5 million private placement. The post Hot Biotech Stocks: Why Celyad Oncology (CYAD) Is Soaring Higher Today ...

1 year ago - InvestorPlace

Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

MONT-SAINT-GUIBERT, Belgium, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the discovery a...

1 year ago - GlobeNewsWire